Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alda S R L currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and is situated in 1 distinct art unit. This indicates a singular focus for the company's current patent prosecution activities, where all regulatory interactions are concentrated within a single department and under a single individual.
Ann Y Montgomery is the busiest examiner for this portfolio, managing 1 pending office action. Because the company has only 1 active matter, its current prosecution outcomes are entirely dependent on the review process within this specific art unit. This streamlined profile suggests a targeted volume of pending intellectual property filings. The reliance on 1 distinct examiner and 1 distinct art unit requires a strategy tailored to the specific standards of the Biotechnology & Pharmaceuticals examination division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTGOMERY, ANN Y | 1 | 69.1% | +27.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564054 | METHOD FOR THE QUANTIFICATION OF THE ACTIVATION STATE OF G-PROTEIN-COUPLED RECEPTORS IN A HUMAN BIOLOGICAL SAMPLE | MONTGOMERY, ANN Y | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564054 | METHOD FOR THE QUANTIFICATION OF THE ACTIVATION STATE OF G-PROTEIN-COUPLED RECEPTORS IN A HUMAN BIOLOGICAL SAMPLE | MONTGOMERY, ANN Y | 1678 | §112 | Non-Final OA | — | Pending | Nov 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlda S R L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ann Y Montgomery has the most, with 1 of Alda S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
